ONCOLOGY THERAPY


Targeting the tumour stroma interface to overcome immunotherapy resistance


 talks to Catherine Pickering, CEO of iOnctura, as the Swiss biotech advances its cancer therapies in the clinic while gearing up to raise funds.


    


C


  


Before launching iOnctura, Pickering


previously worked with pharma giant Merck. “I couldn’t find a company that really inspired me to be the CEO, so I decided to build my own company,” she says. iOnctura was founded in June 2017, when it licensed three programmes developed by Merck KGaA and Cancer Research UK, with whom Pickering


 | 21


Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44